中西医结合治疗对帕金森患者生活质量的影响及临床疗效观察

Influence of Integrated Traditional Chinese and Western Medicine on the Quality of Life in Patients with Parkinson

目的探讨培元通脑胶囊联合常规西药多巴丝肼与泰舒达(吡贝地尔缓释片)治疗帕金森患者的临床疗效以及对生活质量的影响。方法选取2014年6月-2016年6月本院住院治疗的帕金森病患者为研究对象68例,随机分为对照组与观察组各34例。对照组予以多巴丝肼与泰舒达(吡贝地尔缓释片),观察组在对照组基础上加用培元通脑胶囊。对比两组治疗后帕金森病评定量表(UPDRS)评分疗效、中医证候评分及Lawton日常生活能力量表(ADL)评分。结果两组经过治疗,ADL评分均高于治疗前(P<0.05),观察组第四周评分高于对照组,差异具有统计学意义(P<0.05);观察组UPDRS总积分改善率(85.3%)高于对照组(61.8%),差异具有统计学意义(P<0.05);观察组对于震颤、僵直、失眠、便秘、汗出症状有效率明显高于对照组(P<0.05)。结论培元通脑胶囊联合多巴丝肼与泰舒达(吡贝地尔缓释片)能有效改善帕金森患者临床症状,提高生活质量,可作为治疗首选。

Objective To investigate the clinical effect and the quality of life of Peiyuan Tongnao capsule combined with conventional Western medicine benserazide and piribedil on patients with parkinson. Methods 68 cases of patients with Parkinson's disease treated in our hospital from June 2014 to June 2016 were randomly divided into the control group and the observation group, 34 cases in each group. The control group was treated with Yiduobasi hydrazine and piribedil, the observation group was added with Peiyuan Tongnao capsule on the basis of control group. The UPDRS efficacy, TCM syndrome score and the daily living ability of ADL score after the treatment were compared. Results After treatment, the ADL score of two groups were all higher than before treatment(P<0.05), the scores of the treatment group were higher than those of the control group at the first four weeks, the difference was statistically significant(P<0.05). The total score of UPDRS 85.3% of the treatment group was higher than that 61.8% of the control group, and the difference was statistically significant(P<0.05).The effect of tremor, rigidity, insomnia, constipation, sweating symptoms in treatment group was significantly higher than those of the control group(P<0.05). Conclusion Peiyuan Tongnao capsule combined with benserazide and piribedil could effectively improve the clinical symptoms of patients with Parkinson's disease, improve the quality of life.